REFERENCES
2. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol 2017;16:877-97.
3. Dexter DT, Wells FR, Lee AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 1989;52:1830-6.
4. Gonçalves VC, Cuenca-bermejo L, Fernandez-Villalba E, et al. Heart matters: cardiac dysfunction and other autonomic changes in Parkinson’s disease. Neuroscientist 2022;28:530-42.
5. Matzaras R, Shi K, Artemiadis A, et al. Brain neuroimaging of rapid eye movement sleep behavior disorder in Parkinson’s disease: a systematic review. J Parkinsons Dis 2022;12:69-83.
6. Mccormack A, Chegeni N, Chegini F, et al. Purification of α-synuclein containing inclusions from human post mortem brain tissue. J Neurosci Methods 2016;266:141-50.
8. Maroteaux L, Campanelli J, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-15.
9. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha - synuclein gene identified in families with Parkinson’s disease. Science 1997;276:2045-7.
10. Peña-Díaz S, García-Pardo J, Ventura S. Development of small molecules targeting α-synuclein aggregation: a promising strategy to treat Parkinson’s disease. Pharmaceutics 2023;15:839.
11. Yi S, Wang L, Wang H, Ho MS, Zhang S. Pathogenesis of α-synuclein in Parkinson’s disease: from a neuron-glia crosstalk perspective. Int J Mol Sci 2022;23:14753.
12. Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 2023;14:176.
13. Guo YJ, Xiong H, Chen K, Zou JJ, Lei P. Brain regions susceptible to alpha -synuclein spreading. Mol Psychiatry 2022;27:758-70.
14. Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 2017;23:1-13.
15. El-Agnaf OM, Jakes R, Curran MD, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998;440:71-5.
16. Pfefferkorn CM, Jiang Z, Lee JC. Biophysics of α-synuclein membrane interactions. Biochim Biophys Acta 2012;1818:162-71.
17. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein: implications for Parkinson’s disease pathogenesis and therapies. Prog Brain Res 2010;183:115-45.
18. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281:29739-52.
19. Greten-Harrison B, Polydoro M, Morimoto-Tomita M, et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A 2010;107:19573-8.
20. Schechter M, Atias M, Abd Elhadi S, Davidi D, Gitler D, Sharon R. α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2020;295:18076-90.
21. Lundblad M, Decressac M, Mattsson B, Björklund A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 2012;109:3213-9.
22. Wang L, Das U, Scott D, Tang Y, Mclean P, Roy S. α-Synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol 2014;24:2319-26.
23. Atias M, Tevet Y, Sun J, et al. Synapsins regulate α-synuclein functions. Proc Natl Acad Sci U S A 2019;116:11116-8.
24. Yoo G, Shin Y, Lee NK. The Role of α-synuclein in SNARE-mediated synaptic vesicle fusion. J Mol Biol 2023;435:167775.
25. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010;329:1663-7.
26. Choi B, Choi M, Kim J, et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci U S A 2013;110:4087-92.
27. Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol 2018;174:628-43.
28. Blauwendraat C, Makarious MB, Leonard HL, et al. A population scale analysis of rare SNCA variation in the UK biobank. Neurobiol Dis 2021;148:105182.
30. Narhi L, Wood SJ, Steavenson S, et al. Both familial Parkinson’s disease mutations accelerate α-synuclein aggregation. J Biol Chem 1999;274:9843-6.
31. Jiao L, Du X, Jia F, et al. Early low-dose ghrelin intervention via miniosmotic pumps could protect against the progressive dopaminergic neuron loss in Parkinson’s disease mice. Neurobiol Aging 2021;101:70-8.
32. Petrucci S, Ginevrino M, Valente EM. Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models. Parkinsonism Relat Disord 2016;22:S16-20.
33. Kiely AP, Asi YT, Kara E, et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? Acta Neuropathol 2013;125:753-69.
34. Ghosh D, Sahay S, Ranjan P, et al. The newly discovered Parkinson’s disease associated finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding. Biochemistry 2014;53:6419-21.
35. Hoffman-zacharska D, Koziorowski D, Ross OA, et al. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson’s disease. Parkinsonism Relat Disord 2013;19:1057-60.
36. Kumar S, Jangir DK, Kumar R, Kumari M, Bhavesh NS, Maiti TK. Role of sporadic parkinson disease associated mutations A18T and A29S in enhanced α-synuclein fibrillation and cytotoxicity. ACS Chem Neurosci 2018;9:230-40.
37. Ibáñez P, Bonnet A, Débarges B, et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson’s disease. The Lancet 2004;364:1169-71.
38. Chartier-harlin M, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004;364:1167-9.
39. Kéri S, Moustafa AA, Myers CE, Benedek G, Gluck MA. {alpha}-Synuclein gene duplication impairs reward learning. Proc Natl Acad Sci U S A 2010;107:15992-4.
40. Rovelet-Lecrux A, Hannequin D, Guillin O, et al. Frontotemporal dementia phenotype associated with MAPT gene duplication. J Alzheimers Dis 2010;21:897-902.
41. Guennec K, Quenez O, Nicolas G, et al; The CNR-MAJ collaborators. 17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression. Mol Psychiatry 2017;22:1119-25.
42. Chen Z, Chen JA, Shatunov A, et al. NNIPPS and BBBIPPS Study Groups. Genome‐wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov Disord 2019;34:1049-59.
43. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science 2003;302:841.
44. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55:174-9.
45. Sekine T, Kagaya H, Funayama M, et al. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov Disord 2010;25:2871-5.
46. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-53.
47. Chu Y, Muller S, Tavares A, et al. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain 2019;142:3565-79.
48. Bassil F, Meymand ES, Brown HJ, et al. α-Synuclein modulates tau spreading in mouse brains. J Exp Med 2021;218:e20192193.
49. Wu Q, Shaikh MA, Meymand ES, et al. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathol 2020;140:831-49.
50. Mason DM, Nouraei N, Pant DB, et al. Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe. Mol Neurodegener 2016;11:49.
51. Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013;126:555-73.
52. Rey NL, George S, Steiner JA, et al. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol 2018;135:65-83.
53. Rey NL, Steiner JA, Maroof N, et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J Exp Med 2016;213:1759-78.
54. Harms AS, Delic V, Thome AD, et al. α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol Commun 2017;5:85.
55. Luk KC, Kehm VM, Zhang B, O’brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012;209:975-86.
56. Kuan W, Stott K, He X, et al. Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson’s disease. Mol Psychiatry 2021;26:556-67.
57. Challis C, Hori A, Sampson TR, et al. Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat Neurosci 2020;23:327-36.
58. Lohmann S, Bernis ME, Tachu BJ, Ziemski A, Grigoletto J, Tamgüney G. Oral and intravenous transmission of α-synuclein fibrils to mice. Acta Neuropathol 2019;138:515-33.
59. Guo J, Yue F, Song D, et al. Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of macaca fascicularis. Cell Death Dis 2021;12:81.
60. Braak H, Tredici KD, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-211.
61. Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18:101-13.
62. Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain 2020;143:3077-88.
63. Yang W, Li X, Yin N. α-Syn oligomers incubated with Parkinson’s disease plasma promote neuron damage. Int J Clin Exp Pathol 2020;13:1995-2008. Available from:
64. Volpicelli-daley L, Luk K, Patel T, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72:57-71.
65. Cappai R, Leck S, Tew DJ, et al. Dopamine promotes alpha‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway. FASEB J 2005;19:1377-9.
66. Mori A, Imai Y, Hattori N. Lipids: key players that modulate α-synuclein toxicity and neurodegeneration in Parkinson’s disease. Int J Mol Sci 2020;21:3301.
67. Song N, Xie J. Iron, dopamine, and α-synuclein interactions in at-risk dopaminergic neurons in Parkinson’s disease. Neurosci Bull 2018;34:382-4.
68. Galvin JE. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 2006;112:115-26.
69. Latawiec D, Herrera F, Bek A, et al. Modulation of alpha-synuclein aggregation by dopamine analogs. PLoS One 2010;5:e9234.
70. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021;7:47.
71. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001;8:95-100.
72. Med Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014;384:1196-205.
73. Hare DJ, Lei P, Ayton S, et al. An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chem Sci 2014;5:2160-9.
74. Lee H, Baek SM, Ho D, Suk J, Cho E, Lee S. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med 2011;43:216-22.
75. Leong SL, Cappai R, Barnham KJ, Pham CLL. Modulation of α-synuclein aggregation by dopamine: a review. Neurochem Res 2009;34:1838-46.
76. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002;22:3090-9.
77. Lhermitte J, Kraus WM, Mcalpine D. Original papers: on the occurrence of abnormal deposits of iron in the brain in parkinsonism with special reference to its localisation. J Neurol Psychopathol 1924;5:195-208.
78. Hirsch EC, Brandel J, Galle P, Javoy-agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 1991;56:446-51.
79. Xiong H, Tuo Q, Guo Y, Lei P. Diagnostics and treatments of iron-related CNS diseases. In: Chang Y, editor. Brain Iron Metabolism and CNS Diseases. Singapore: Springer; 2019. pp. 179-94.
80. Lei P, Ayton S, Bush AI. Axonal dispatch of iron in neuronal signaling. Nat Chem Biol 2019;15:1135-6.
81. Dexter DT, Carayon A, Javoy-agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-75.
82. Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012;18:291-5.
83. Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007;68:1820-5.
84. Friedrich I, Reimann K, Jankuhn S, et al. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson’s disease. Acta Neuropathol Commun 2021;9:47.
85. Martin-bastida A, Lao-kaim NP, Loane C, et al. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson’s disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. Eur J Neurol 2017;24:357-65.
86. Guan X, Xuan M, Gu Q, et al. Regionally progressive accumulation of iron in Parkinson’s disease as measured by quantitative susceptibility mapping: NMR Biomed 2017;30:e3489.
87. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson’s disease and is a sufficient cause of neurodegeneration. Biomed Res Int 2014;2014:581256.
88. Lei P, Ayton S, Appukuttan AT, et al. Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry 2017;22:396-406.
89. Lei P, Ayton S, Bush AI. The essential elements of Alzheimer’s disease. J Biol Chem 2021;296:100105.
90. Lei P, Ayton S, Moon S, et al. Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener 2014;9:29.
91. Ayton S, Lei P, Hare DJ, et al. Parkinson’s disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein. J Neurosci 2015;35:3591-7.
92. Han J, Fan Y, Wu P, et al. Parkinson’s disease dementia: synergistic effects of alpha-synuclein, tau, beta-amyloid, and iron. Front Aging Neurosci 2021;13:743754.
93. Finkelstein DI, Billings JL, Adlard PA, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease. Acta Neuropathol Commun 2017;5:53.
94. Ostrerova-Golts N, Petrucelli L, Hardy J, et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000;20:6048-54.
95. Friedlich AL, Tanzi RE, Rogers JT. The 5’-untranslated region of Parkinson’s disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry 2007;12:222-3.
96. Rogers JT, Mikkilineni S, Cantuti-castelvetri I, et al. The alpha-synuclein 5’untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm 2011;118:493-507.
97. Wu J, Tuo Q, Lei P. Ferroptosis, a recent defined form of critical cell death in neurological disorders. J Mol Neurosci 2018;66:197-206.
98. Zhou ZD, Tan E. Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases. Mol Neurodegener 2017;12:75.
99. Yan H, Zou T, Tuo Q, et al. Ferroptosis: mechanisms and links with diseases. Sig Transduct Target Ther 2021;6:49.
100. Wang R, Wang Y, Qu L, et al. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2. Neurochem Int 2019;125:127-35.
101. Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal 2014;21:195-210.
102. Shukla JJ, Stefanova N, Bush AI, McColl G, Finkelstein DI, McAllum EJ. Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. Neurobiol Dis 2021;159:105509.
103. Finkelstein DI, Shukla JJ, Cherny RA, et al. The compound ATH434 prevents alpha-synuclein toxicity in a murine model of multiple system atrophy. J Parkinsons Dis 2022;12:105-15.
104. Dauer Née Joppe K, Tatenhorst L, Caldi Gomes L, et al. Brain iron enrichment attenuates α-synuclein spreading after injection of preformed fibrils. J Neurochem 2021;159:554-73.
105. McLeary FA, Rcom-H’cheo-Gauthier AN, Goulding M, et al. Switching on endogenous metal binding proteins in Parkinson’s disease. Cells 2019;8:179.
106. Valiente-Gabioud AA, Torres-Monserrat V, Molina-Rubino L, Binolfi A, Griesinger C, Fernández CO. Structural basis behind the interaction of Zn²⁺ with the protein α-synuclein and the Aβ peptide: a comparative analysis. J Inorg Biochem 2012;117:334-41.
107. Ranjan P, Ghosh D, Yarramala DS, Das S, Maji SK, Kumar A. Differential copper binding to alpha-synuclein and its disease-associated mutants affect the aggregation and amyloid formation. Biochim Biophys Acta Gen Subj 2017;1861:365-74.
108. Li Y, Yu Y, Ma G. Modulation Effects of Fe3+, Zn2+, and Cu2+ Ions on the amyloid fibrillation of α-synuclein: insights from a FTIR investigation. Molecules 2022;27:8383.
109. Galvagnion C, Buell AK, Meisl G, et al. Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol 2015;11:229-34.
110. Kiechle M, Grozdanov V, Danzer KM. The role of lipids in the initiation of α-synuclein misfolding. Front Cell Dev Biol 2020;8:562241.
111. Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and risk of Parkinson’s disease. J Parkinsons Dis 2021;11:31-43.
112. Reish HE, Standaert DG. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 2015;5:1-19.
113. Prigent A, Lionnet A, Durieu E, et al. Enteric alpha-synuclein expression is increased in Crohn’s disease. Acta Neuropathol 2019;137:359-61.
114. Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P. Upregulation of α-synuclein following immune activation: possible trigger of Parkinson’s disease. Neurobiol Dis 2022;166:105654.
115. Kim C, Lv G, Lee JS, et al. Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril. Sci Rep 2016;6:30891.
116. Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 2020;16:97-107.
117. Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015;72:100-5.
118. Poulopoulos M, Cortes E, Vonsattel JP, et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci 2012;47:139-43.
120. Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F. Motor phenotype of LRRK2-associated Parkinson’s disease: a Tunisian longitudinal study. Mov Disord 2015;30:253-8.
121. Bieri G, Brahic M, Bousset L, et al. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol 2019;137:961-80.
122. Obergasteiger J, Frapporti G, Lamonaca G, et al. Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions. Cell Death Discov 2020;6:45.
123. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Sci Transl Med 2018;10:eaar5429.
124. Kim C, Beilina A, Smith N, et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med 2020;12:eaay0399.
125. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
126. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 2014;71:62-7.
127. Li X, Gehring K. Structural studies of parkin and sacsin: mitochondrial dynamics in neurodegenerative diseases. Mov Disord 2015;30:1610-9.
128. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson’s disease in a large pedigree with 77 parkin mutation carriers. Ann Neurol 2005;58:411-22.
129. Seike N, Yokoseki A, Takeuchi R, et al. Genetic variations and neuropathologic features of patients with PRKN mutations. Mov Disord 2021;36:1634-43.
130. Lo Bianco C, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101:17510-5.
131. LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG. The effects of oxidative stress on parkin and other E3 ligases. J Neurochem 2007;103:2354-68.
132. Rocha Cabrero F, Morrison EH. Lewy Bodies. In: StatPearls; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536956/. [Last accessed on 27 Jun 2023].
133. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 2010;25:642-6.
134. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson’s disease? Neurobiol Dis 2007;25:134-49.
135. Wilhelmus MMM, Chouchane O, Loos M, et al. Absence of tissue transglutaminase reduces amyloid-beta pathology in APP23 mice. Neuropathol Appl Neurobiol 2022;48:e12796.
136. Li X, Lei P, Tuo Q, et al. Enduring elevations of hippocampal amyloid precursor protein and iron are features of β-amyloid toxicity and are mediated by tau. Neurotherapeutics 2015;12:862-73.
137. Ghosh S, Ali R, Verma S. Aβ-oligomers: a potential therapeutic target for Alzheimer’s disease. Int J Biol Macromol 2023;239:124231.
138. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9-21.
139. Alves F, Kalinowski P, Ayton S. Accelerated brain volume loss caused by anti-β-amyloid drugs: a systematic review and meta-analysis. Neurology 2023;100:e2114-24.
140. Lohmann E, Hanağası HA, Gürvit H, et al. The impact of familial structure on Parkinson’s disease in istanbul medical school, turkey. Int J Neurosci 2012;122:102-5.
141. Proukakis C, Dudzik CG, Brier T, et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013;80:1062-4.
142. Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, et al. Low prevalence of known pathogenic mutations in dominant PD genes: a Swedish multicenter study. Parkinsonism Relat Disord 2019;66:158-65.
143. Tan LY, Tang KH, Lim LYY, Ong JX, Park H, Jung S. α-Synuclein at the presynaptic axon terminal as a double-edged sword. Biomolecules 2022;12:507.
144. Bozi M, Papadimitriou D, Antonellou R, et al. Genetic assessment of familial and early-onset Parkinson’s disease in a Greek population. Eur J Neurol 2014;21:963-8.
145. Papadimitriou D, Antonelou R, Miligkos M, et al. Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study. Mov Disord 2016;31:1226-30.
146. Markopoulou K, Dickson DW, McComb RD, et al. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson’s disease. Variability in familial Parkinson’s disease. Acta Neuropathol 2008;116:25-35.
147. Goldwurm S, Di Fonzo A, Simons EJ, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor. J Med Genet 2005;42:e65.
148. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson’s disease in central Norway. Ann Neurol 2005;57:762-5.
149. Lin CH, Chen PL, Tai CH, et al. A clinical and genetic study of early-onset and familial parkinsonism in taiwan: an integrated approach combining gene dosage analysis and next-generation sequencing. Mov Disord 2019;34:506-15.
150. Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010;133:1128-42.
151. Ishihara-Paul L, Hulihan MM, Kachergus J, et al. PINK1 mutations and parkinsonism. Neurology 2008;71:896-902.
152. Tan AH, Lohmann K, Tay YW, et al. PINK1 p.Leu347Pro mutations in Malays: prevalence and illustrative cases. Parkinsonism Relat Disord 2020;79:34-9.
153. Kasten M, Weichert C, Lohmann K, Klein C. Clinical and demographic characteristics of PINK1 mutation carriers - a meta-analysis. Mov Disord 2010;25:952-4.
154. Ephraty L, Porat O, Israeli D, et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007;22:566-9.
155. Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 2016;86:2212-3.
156. Nybø CJ, Gustavsson EK, Farrer MJ, Aasly JO. Neuropathological findings in PINK1-associated Parkinson’s disease. Parkinsonism Relat Disord 2020;78:105-8.
157. Castelo Rueda MP, Raftopoulou A, Gögele M, et al. Frequency of heterozygous parkin (PRKN) variants and penetrance of Parkinson’s disease risk markers in the population-based CHRIS cohort. Front Neurol 2021;12:706145.
158. Hedrich K, Djarmati A, Schäfer N, et al. DJ-1 (PARK7) mutations are less frequent than parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 2004;62:389-94.
159. Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005;65:1460-1.
160. Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011;77:276-80.
161. Ren J, Zhang R, Pan C, et al. Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort. Eur J Neurol 2022;29:1017-24.
162. Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009;66:578-83.
